查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1859714

外泌体诊断和治疗市场预测至2032年：按产品/服务、来源、类型、技术、最终用户和地区分類的全球分析

Exosome Diagnostics and Therapeutics Market Forecasts to 2032 - Global Analysis By Product & Service (Instruments, Reagents & Kits, Software, Services and Consumables), Source, Type, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球外泌体诊断和治疗市场规模将达到 1.0808 亿美元，到 2032 年将达到 74.861 亿美元，预测期内复合年增长率将达到 83.2%。

外泌体诊断和治疗涉及对细胞释放的携带蛋白质、脂质和核酸的小型细胞外囊泡的研究和应用，旨在将其作为疾病检测和治疗的工具。在诊断方面，外泌体可作为非侵入性生物标记物，透过液态切片即时监测癌症、神经退化性疾病和心血管疾病等病理状况。在治疗方面，可以透过基因工程改造外泌体，使其能够将药物、RNA和基因编辑分子直接递送至目标细胞，从而提高治疗精准度并减少副作用。该领域充分利用了外泌体的天然生物相容性、稳定性和细胞特异性靶向潜力，使其成为个人化医疗和下一代临床干预的理想平台。

增加研究经费和政府支持

公共和私人基金会正在投资基于外泌体的液体液态切片，用于癌症筛检和再生医学。该平台支援肿瘤学、神经病学和感染疾病的生物标记发现、药物递送和免疫调节。与学术研究型医院网路和培养箱的整合增强了检验和扩充性。转化医学和个人化医疗计画正在推动对非侵入性、精准工具的需求。这些因素正在推动该平台在以研究为密集、创新主导的医疗保健生态系统中广泛应用。

缺乏标准化通讯协定

不同实验室供应商和治疗药物开发商的分离鑑定和定量方法差异很大。纯度标记、载重分析和功能检测方面缺乏共识，使得验证和监管申报变得复杂。企业在比较不同研究的数据以及在GMP条件下扩大生产规模方面面临挑战。监管机构要求采用统一的标准来评估诊断和治疗应用中的安全性、有效性和品质。这些限制阻碍了平台成熟度和跨领域整合。

慢性病和感染疾病的流行情况

外泌体在癌症、心血管疾病和神经退化性疾病的早期检测、疾病监测和标靶递送方面具有独特的优势。相关平台支援透过液态切片进行免疫分析，并利用基于RNA的有效载荷进行治疗调控。与主导的分析和多组体学工作流程的整合，可提高灵敏度、特异性和临床效用。在人口老化和疾病负担沉重的地区，对可扩展、微创解决方案的需求日益增长。这些趋势正在推动以疾病为中心的外泌体创新和应用的发展。

高昂的成本和基础设施需求

分离纯化需要微流体技术和奈米颗粒追踪系统，这导致巨大的资本和营运成本。在GMP条件下进行生产和临床级验证进一步增加了成本和复杂性。小规模实验室和新兴生物技术公司在获得可扩展生产的资金和基础设施方面面临挑战。缺乏保险报销和有限的临床指南进一步限制了该技术在诊断和治疗领域的应用。这些限制持续限制该平台在资源匮乏且分散的医疗环境中的部署。

新冠疫情的影响：

疫情扰乱了整个外泌体平台的临床试验供应链和研究项目。封锁和资源重新分配延缓了样本采集、检测方法开发和监管审批。然而，随着研究人员对免疫反应、病毒持续存在和长期后遗症的研究，人们对基于外泌体的诊断方法的兴趣激增。对远端液态切片采样和数位病理学的投资加速了平台创新和部署。消费者和临床领域对分子诊断和个人化医疗的认知度不断提高。这些变化强化了对外泌体基础设施和转化研究的长期投资。

预计在预测期内，诊断业务板块将成为最大的业务板块。

由于临床相关检测技术的成熟以及其在疾病领域的广泛应用，预计在预测期内，诊断领域将占据最大的市场份额。基于外泌体的诊断技术利用RNA、蛋白质和脂质生物标记物，支持早期检测、预后和治疗监测。该平台采用液态切片和免疫测量，从血液、尿液和唾液中分离和分析外泌体。结合人工智慧主导的解读和多组体学分析，可提高检测的敏感度、特异性和长期追踪能力。肿瘤学、感染疾病、神经退化等领域对非侵入性且可扩展的诊断技术的需求日益增长。

预计在预测期内，干细胞领域将以最高的复合年增长率成长。

预计在预测期内，干细胞领域将呈现最高的成长速度，因为外泌体疗法正拓展至再生医学和免疫调节领域。干细胞来源的外泌体在整形外科、心血管和神经系统疾病中发挥组织修復、发炎控制和神经保护的作用。间质干细胞和诱导性多功能干细胞是实现规模化生产、载体工程和靶向递送的理想平台。与生物材料和3D支架的整合能够提高治疗效果和标靶性。在高龄化社会和慢性病族群中，对无细胞、免疫安全性高的治疗方法的需求日益增长。这些趋势正在推动干细胞来源的外泌体疗法和递送平台的发展。

占比最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的研究基础设施、积极的监管参与以及外泌体平台在临床上的广泛应用。企业和学术机构正在肿瘤学、神经病学和感染疾病计画中部署诊断和治疗方法，并整合定序和生物资讯工作流程。对液态切片活检转化研究和个人化医疗的投资支持了扩充性和检验。领先的诊断研究中心和监管机构的存在推动了创新和标准化。各公司正根据FDA指南、NIH资助和支付方参与情况调整其平台策略。这些因素共同推动了北美在外泌体商业化和临床整合的领先地位。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率，这得益于医疗现代化降低了疾病负担，以及生物技术投资在区域经济中的汇聚。中国、印度、日本和韩国等国家正在公共卫生、学术研究和新兴企业诊断领域推广外泌体平台。政府支持的倡议正在推动基础设施建设、新创公司孵化以及生物标记发现和治疗方法检验的国际合作。本地企业正在提供经济高效且符合当地实际情况的解决方案，以满足疾病特征和合规性需求。肿瘤学、感染疾病、再生医学等领域对可扩展且符合当地文化的外泌体平台的需求正在成长。

免费客製化服务：

订阅本报告的用户可享有以下免费客製化服务之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 研究方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究方法
  • 研究材料
    • 原始研究资料
    • 二手研究资料
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球外泌体诊断和治疗市场（按产品和服务划分）

  • 装置
  • 试剂和试剂盒
  • 软体
  • 服务
  • 消耗品

6. 全球外泌体诊断与治疗市场（依来源划分）

  • 血
  • 电浆
  • 尿
  • 干细胞
  • 其他来源

7. 全球外泌体诊断与治疗市场（按类型划分）

  • 诊断
  • 治疗药物
  • 研究用途

8. 全球外泌体诊断与治疗市场（依技术划分）

  • 外泌体分离技术
    • 超速离心
    • 尺寸排阻层析法
    • 亲和性和捕获
    • 微流体
  • 表征工具
    • NTA（奈米颗粒追踪分析）
    • 穿透式电子显微镜（TEM）
    • 扫描电子显微镜（SEM）
    • 西方印渍术
    • 流式细胞技术
  • 其他技术

9. 全球外泌体诊断与治疗市场（依最终使用者划分）

  • 医院和诊所
  • 诊断检查室
  • 癌症研究所
  • 学术和研究机构
  • 生物製药公司
  • 其他最终用户

第十章 全球外泌体诊断与治疗市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Thermo Fisher Scientific Inc.
  • Lonza Group AG
  • Catalent Inc.
  • Fujifilm Diosynth Biotechnologies Inc.
  • WuXi Advanced Therapies Inc.
  • Samsung Biologics Co., Ltd.
  • AGC Biologics Inc.
  • Minaris Regenerative Medicine GmbH
  • Oxford Biomedica plc
  • Charles River Laboratories International Inc.
  • Recipharm AB
  • Merck KGaA
  • Takara Bio Inc.
  • Miltenyi Biotec BV & Co. KG
  • BioNTech SE
Product Code: SMRC31938

According to Stratistics MRC, the Global Exosome Diagnostics and Therapeutics Market is accounted for $108.08 million in 2025 and is expected to reach $7486.1 million by 2032 growing at a CAGR of 83.2% during the forecast period. Exosome diagnostics and therapeutics involve the study and application of exosomes tiny extracellular vesicles released by cells that carry proteins, lipids, and nucleic acids-as tools for disease detection and treatment. In diagnostics, exosomes serve as non-invasive biomarkers, providing real-time insights into conditions like cancer, neurodegenerative disorders, and cardiovascular diseases through liquid biopsies. Therapeutically, engineered exosomes can deliver drugs, RNA, or gene-editing molecules directly to target cells, enhancing precision and reducing side effects. The field leverages exosomes' natural biocompatibility, stability, and cell-specific targeting potential, making them a promising platform for personalized medicine and next-generation clinical interventions.

Market Dynamics:

Driver:

Increased research funding and government support

Public agencies and private foundations are investing in exosome-based liquid biopsy cancer screening and regenerative medicine. Platforms support biomarker discovery drug delivery and immune modulation across oncology neurology and infectious diseases. Integration with academic research hospital networks and biotech incubators enhances validation and scalability. Demand for non-invasive and precision-focused tools is rising across translational and personalized medicine programs. These dynamics are propelling platform deployment across research-intensive and innovation-driven healthcare ecosystems.

Restraint:

Lack of standardized protocols

Isolation characterization and quantification methods vary widely across labs vendors and therapeutic developers. Absence of consensus on purity markers cargo profiling and functional assays complicates validation and regulatory submission. Enterprises face challenges in comparing data across studies and scaling manufacturing under GMP conditions. Regulatory bodies require harmonized standards to assess safety efficacy and quality across diagnostic and therapeutic applications. These constraints continue to hinder platform maturity and cross-sector integration.

Opportunity:

Growing prevalence of chronic and infectious diseases

Exosomes offer unique advantages in early detection disease monitoring and targeted delivery across cancer cardiovascular and neurodegenerative conditions. Platforms support liquid biopsy immune profiling and RNA-based payloads for therapeutic modulation. Integration with AI-driven analytics and multi-omics workflows enhances sensitivity specificity and clinical utility. Demand for scalable and minimally invasive solutions is rising across aging populations and high-burden disease areas. These trends are fostering growth across disease-centric exosome innovation and deployment.

Threat:

High costs and infrastructure requirements

Isolation and purification require ultracentrifugation microfluidics and nanoparticle tracking systems with high capital and operational expenditure. Manufacturing under GMP conditions and clinical-grade validation adds to cost and complexity. Smaller labs and emerging biotech firms face challenges in securing funding and infrastructure for scalable production. Lack of reimbursement and limited clinical guidelines further constrain adoption across diagnostic and therapeutic settings. These limitations continue to restrict platform deployment across resource-constrained and decentralized healthcare environments.

Covid-19 Impact:

The pandemic disrupted clinical trials supply chains and research programs across exosome platforms. Lockdowns and resource reallocation delayed sample collection assay development and regulatory review. However interest in exosome-based diagnostics surged as researchers explored immune response viral persistence and long-term sequelae. Investment in liquid biopsy remote sampling and digital pathology accelerated platform innovation and deployment. Public awareness of molecular diagnostics and personalized medicine increased across consumer and clinical segments. These shifts are reinforcing long-term investment in exosome infrastructure and translational research.

The diagnostics segment is expected to be the largest during the forecast period

The diagnostics segment is expected to account for the largest market share during the forecast period due to its clinical relevance assay maturity and broad applicability across disease areas. Exosome-based diagnostics support early detection prognosis and treatment monitoring using RNA proteins and lipid biomarkers. Platforms use liquid biopsy microfluidics and immunoassays to isolate and analyze exosomes from blood urine and saliva. Integration with AI-driven interpretation and multi-omics profiling enhances sensitivity specificity and longitudinal tracking. Demand for non-invasive and scalable diagnostics is rising across oncology infectious diseases and neurodegeneration.

The stem cells segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the stem cells segment is predicted to witness the highest growth rate as exosome therapeutics expand across regenerative medicine and immune modulation. Stem cell-derived exosomes support tissue repair inflammation control and neuroprotection across orthopedic cardiovascular and neurological indications. Platforms enable scalable production cargo engineering and targeted delivery using mesenchymal and induced pluripotent stem cells. Integration with biomaterials and 3D scaffolds enhances therapeutic efficacy and localization. Demand for cell-free and immunologically safe therapies is rising across aging populations and chronic disease cohorts. These dynamics are accelerating growth across stem cell-derived exosome therapeutics and delivery platforms.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure regulatory engagement and clinical adoption across exosome platforms. Enterprises and academic institutions deploy diagnostics and therapeutics across oncology neurology and infectious disease programs with integrated sequencing and bioinformatics workflows. Investment in liquid biopsy translational research and personalized medicine supports scalability and validation. Presence of leading diagnostic firms research centers and regulatory bodies drives innovation and standardization. Firms align platform strategies with FDA guidance NIH funding and payer engagement. These factors are propelling North America's leadership in exosome commercialization and clinical integration.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization disease burden and biotech investment converge across regional economies. Countries like China India Japan and South Korea scale exosome platforms across public health academic research and clinical diagnostics. Government-backed initiatives support infrastructure development startup incubation and international collaboration across biomarker discovery and therapeutic validation. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. Demand for scalable and culturally aligned exosome platforms is rising across oncology infectious diseases and regenerative medicine.

Key players in the market

Some of the key players in Exosome Diagnostics and Therapeutics Market include Thermo Fisher Scientific Inc., Bio-Techne Corporation, QIAGEN N.V., System Biosciences LLC, ReNeuron Group plc, Hitachi Chemical Diagnostics Inc., Capricor Therapeutics Inc., Evox Therapeutics Limited, Capital Biosciences Inc., Exogenus Therapeutics S.A., Exo Biologics S.A., AMSBIO LLC, Lonza Group AG, NanoView Biosciences Inc. and Aethlon Medical Inc.

Key Developments:

In August 2025, Bio-Techne announced the divestiture of Exosome Diagnostics Inc. to Mdxhealth SA, including the ExoDx Prostate (EPI) test, its CLIA-certified clinical laboratory, and related assets. The deal enables Mdxhealth to expand its urology diagnostics portfolio, while Bio-Techne retains access to proprietary exosome-based technology for future kit development under its precision diagnostics growth pillar.

In April 2025, Thermo Fisher introduced ExoTrack(TM) Ultra, a next-gen exosome isolation and profiling kit designed for liquid biopsy applications. The product supports high-yield recovery and multiplexed biomarker detection, enabling early-stage cancer diagnostics and neurodegenerative disease monitoring. It integrates seamlessly with Thermo's mass spectrometry and NGS platforms, enhancing translational research and clinical workflows.

Product & Services Covered:

  • Instruments
  • Reagents & Kits
  • Software
  • Services
  • Consumables

Sources Covered:

  • Blood
  • Plasma
  • Urine
  • Stem Cells
  • Other Sources

Types Covered:

  • Diagnostics
  • Therapeutics
  • Research Use

Technologies Covered:

  • Exosome Isolation Techniques
  • Characterization Tools
  • Other Technologies

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Cancer Institutes
  • Academic & Research Institutions
  • Biopharma Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Exosome Diagnostics and Therapeutics Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Reagents & Kits
  • 5.4 Software
  • 5.5 Services
  • 5.6 Consumables

6 Global Exosome Diagnostics and Therapeutics Market, By Source

  • 6.1 Introduction
  • 6.2 Blood
  • 6.3 Plasma
  • 6.4 Urine
  • 6.5 Stem Cells
  • 6.6 Other Sources

7 Global Exosome Diagnostics and Therapeutics Market, By Type

  • 7.1 Introduction
  • 7.2 Diagnostics
  • 7.3 Therapeutics
  • 7.4 Research Use

8 Global Exosome Diagnostics and Therapeutics Market, By Technology

  • 8.1 Introduction
  • 8.2 Exosome Isolation Techniques
    • 8.2.1 Ultracentrifugation
    • 8.2.2 Size-Exclusion Chromatography
    • 8.2.3 Immunoaffinity Capture
    • 8.2.4 Microfluidics
  • 8.3 Characterization Tools
    • 8.3.1 NTA (Nanoparticle Tracking Analysis)
    • 8.3.2 TEM (Transmission Electron Microscopy)
    • 8.3.3 SEM (Scanning Electron Microscopy)
    • 8.3.4 Western Blotting
    • 8.3.5 Flow Cytometry
  • 8.4 Other Technologies

9 Global Exosome Diagnostics and Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Cancer Institutes
  • 9.5 Academic & Research Institutions
  • 9.6 Biopharma Companies
  • 9.7 Other End Users

10 Global Exosome Diagnostics and Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 Lonza Group AG
  • 12.3 Catalent Inc.
  • 12.4 Fujifilm Diosynth Biotechnologies Inc.
  • 12.5 WuXi Advanced Therapies Inc.
  • 12.6 Samsung Biologics Co., Ltd.
  • 12.7 AGC Biologics Inc.
  • 12.8 Minaris Regenerative Medicine GmbH
  • 12.9 Oxford Biomedica plc
  • 12.10 Charles River Laboratories International Inc.
  • 12.11 Recipharm AB
  • 12.12 Merck KGaA
  • 12.13 Takara Bio Inc.
  • 12.14 Miltenyi Biotec B.V. & Co. KG
  • 12.15 BioNTech SE

List of Tables

  • Table 1 Global Exosome Diagnostics and Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Exosome Diagnostics and Therapeutics Market Outlook, By Product & Service (2024-2032) ($MN)
  • Table 3 Global Exosome Diagnostics and Therapeutics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Exosome Diagnostics and Therapeutics Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 5 Global Exosome Diagnostics and Therapeutics Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Exosome Diagnostics and Therapeutics Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Exosome Diagnostics and Therapeutics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Exosome Diagnostics and Therapeutics Market Outlook, By Source (2024-2032) ($MN)
  • Table 9 Global Exosome Diagnostics and Therapeutics Market Outlook, By Blood (2024-2032) ($MN)
  • Table 10 Global Exosome Diagnostics and Therapeutics Market Outlook, By Plasma (2024-2032) ($MN)
  • Table 11 Global Exosome Diagnostics and Therapeutics Market Outlook, By Urine (2024-2032) ($MN)
  • Table 12 Global Exosome Diagnostics and Therapeutics Market Outlook, By Stem Cells (2024-2032) ($MN)
  • Table 13 Global Exosome Diagnostics and Therapeutics Market Outlook, By Other Sources (2024-2032) ($MN)
  • Table 14 Global Exosome Diagnostics and Therapeutics Market Outlook, By Type (2024-2032) ($MN)
  • Table 15 Global Exosome Diagnostics and Therapeutics Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 16 Global Exosome Diagnostics and Therapeutics Market Outlook, By Therapeutics (2024-2032) ($MN)
  • Table 17 Global Exosome Diagnostics and Therapeutics Market Outlook, By Research Use (2024-2032) ($MN)
  • Table 18 Global Exosome Diagnostics and Therapeutics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 19 Global Exosome Diagnostics and Therapeutics Market Outlook, By Exosome Isolation Techniques (2024-2032) ($MN)
  • Table 20 Global Exosome Diagnostics and Therapeutics Market Outlook, By Ultracentrifugation (2024-2032) ($MN)
  • Table 21 Global Exosome Diagnostics and Therapeutics Market Outlook, By Size-Exclusion Chromatography (2024-2032) ($MN)
  • Table 22 Global Exosome Diagnostics and Therapeutics Market Outlook, By Immunoaffinity Capture (2024-2032) ($MN)
  • Table 23 Global Exosome Diagnostics and Therapeutics Market Outlook, By Microfluidics (2024-2032) ($MN)
  • Table 24 Global Exosome Diagnostics and Therapeutics Market Outlook, By Characterization Tools (2024-2032) ($MN)
  • Table 25 Global Exosome Diagnostics and Therapeutics Market Outlook, By NTA (Nanoparticle Tracking Analysis) (2024-2032) ($MN)
  • Table 26 Global Exosome Diagnostics and Therapeutics Market Outlook, By TEM (Transmission Electron Microscopy) (2024-2032) ($MN)
  • Table 27 Global Exosome Diagnostics and Therapeutics Market Outlook, By SEM (Scanning Electron Microscopy) (2024-2032) ($MN)
  • Table 28 Global Exosome Diagnostics and Therapeutics Market Outlook, By Western Blotting (2024-2032) ($MN)
  • Table 29 Global Exosome Diagnostics and Therapeutics Market Outlook, By Flow Cytometry (2024-2032) ($MN)
  • Table 30 Global Exosome Diagnostics and Therapeutics Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 31 Global Exosome Diagnostics and Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Exosome Diagnostics and Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 33 Global Exosome Diagnostics and Therapeutics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Exosome Diagnostics and Therapeutics Market Outlook, By Cancer Institutes (2024-2032) ($MN)
  • Table 35 Global Exosome Diagnostics and Therapeutics Market Outlook, By Academic & Research Institutions (2024-2032) ($MN)
  • Table 36 Global Exosome Diagnostics and Therapeutics Market Outlook, By Biopharma Companies (2024-2032) ($MN)
  • Table 37 Global Exosome Diagnostics and Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.